All but two of the variables most predictive of who’s likely to die on the heart transplant waitlist are included in the allocation system for donor hearts, finds an analysis of the SRTR national database.
Risk is dynamic for patients on the heart transplant waitlist. We’ve developed a decision aid for risk estimation that reflects that fact, with the hope of ultimately reducing waitlist deaths.
60,000 Americans die of drug overdose each year. Obtaining hearts from just a fraction would meet the needs of the 3,900-plus people on the transplant waitlist. Here’s how we’re helping make that happen.
The funding will support a three-pronged initiative using machine learning and other methods to identify factors behind survival disparities to improve survival and minimize organ wastage.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Cleveland Clinic Abu Dhabi achieves medical milestone, completing the United Arab Emirates’ first full heart transplant.
When ECMO isn’t enough: How a newborn with a single ventricle survived on a VAD and made it to transplant
A patient on immunosuppressants after transplantation grows debilitating plantar warts on her feet.
When a Fontan procedure fails, a ventricular assist device can be used to boost the single ventricle’s pumping power, buying time to transplant
Cleveland Clinic has launched one of the nation’s few outpatient palliative care services for patients with advanced heart disease. We share insights on its purposes and best practices.
The MOMENTUM 3 trial is doing more than assessing the HeartMate 3’s novel mag-lev technology. It also reflects the fading distinction between bridge and destination LVAD therapy.